TRACER

TRACER is a biotechnology startup founded in 2017 with a focus on accelerating clinical trials through early and accurate in-human data generation for drugs using molecular imaging techniques. The company specializes in first-in-human studies, leveraging nuclear and optical molecular imaging to label various compounds for fast data acquisition on potential drug efficacy, even preceding the traditional phase 1-3 clinical trials. This approach ultimately aims to streamline and reduce the cost of the drug development process. TRACER collaborates with sponsors to label lead compounds and conduct first-in-human studies to visualize and quantify biodistribution and pharmacokinetics, enabling informed "go/no-go" decisions before progressing to the next phase of clinical development. Notably, early in-human studies are EMA and FDA-approved through the principle of microdosing, potentially bypassing extensive animal models. Currently, there is no publicly available information on the last investment or the investors involved in TRACER.